聯營新疆戈恩斯派息及資本削減 協鑫科技(03800.HK)虧損近40億人民幣
協鑫科技(03800.HK)公布,聯營新疆戈恩斯議決向部分股東(包括江蘇中能及TCL)分派股息及資本削減。完成後,江蘇中能將不再持有新疆戈恩斯的任何直接股權。集團將確認本交易的虧損約39.74億人民幣(下同),集團並將徹底退出多晶硅西門子法棒狀硅經營領域,專注於硅烷流化床法顆粒硅技術研發與生產。
其中涉及分別向江蘇中能及TCL宣派股息44.73億元及31.37億元;及因資本削減向江蘇中能及TCL分別支付9.93億元及6.97億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.